On April 25, 2019 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, reported that it will present first quarter 2019 results and operational highlights in a conference call on May 2, 2019 at 8 a.m. ET (Press release, Intellia Therapeutics, APR 25, 2019, View Source [SID1234535546]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The investor presentation may be downloaded starting at 7:30 a.m. ET from the Events and Presentations page of the Investor Relations section of Intellia’s website at intelliatx.com.

To join the call:

U.S. callers should dial 800-458-4148 and use conference ID# 7725705, approximately five minutes before the call.
International callers should click here to access dial-in information and use conference ID# 7725705, approximately five minutes before the call.
A replay of the call will be available on Intellia’s website, beginning on May 2, 2019 at 12 p.m. ET.